title: [Treatment with immunomodulating drugs of patients with operated cancer. Long-term results].
abstract: The authors produce a new course of study in order to verify the efficacy of immunomodulatory treatment in cancer-operated patients. In the General Surgical Clinic and Surgical Therapy Institute of University of Ferrara, from July '86 to June '92, 582 cancer-operated patients were treated by immunomodulatory drugs, making use of standard of absolute random. A group (100 patients) was subjected to peroperative anticontagious immunoprophylaxis; B group (482 patients) to postoperative cyclic immunomodulation; in this last group, were codified C group (166 patients) and D group (63 patients), controlled in follow-up, making use of 3 parameters: survival, clinical-oncological restage, performance status. The results obtained confirm the efficacy of the proposed immunomodulatory treatment: a reduction of incidence both early infections and late infections, an increase of survival, falls in clinical-oncological stage to less advanced levels and, above all, an improvement of performance status.
authors.affiliation: Istituto di Clinica Chirurgica Generale e Terapia Chirurgica, Università degli Studi di Ferrara.
authors.forename: A
authors.initials: A
authors.lastname: Sortini
authors.forename: L
authors.initials: L
authors.lastname: Di Marco
authors.forename: G
authors.initials: G
authors.lastname: Navarra
authors.forename: A
authors.initials: A
authors.lastname: Donini
authors.forename: G
authors.initials: G
authors.lastname: Fiorentini
authors.forename: M
authors.initials: M
authors.lastname: Santini
authors.forename: A
authors.initials: A
authors.lastname: Sartori
authors.forename: I
authors.initials: I
authors.lastname: Donini
mesh_terms: D000276:Adjuvants, Immunologic / Q000627:therapeutic use*; D002444:Cefuroxime / Q000627:therapeutic use; D005500:Follow-Up Studies; D006801:Humans; D007369:Interferon Inducers / Q000627:therapeutic use; D009369:Neoplasms / Q000401:mortality / Q000601:surgery*; D011182:Postoperative Care; D016305:Thymopentin / Q000627:therapeutic use; D013949:Thymus Extracts / Q000627:therapeutic use; D013997:Time Factors
chemical_list: D000276:Adjuvants, Immunologic; D007369:Interferon Inducers; D013949:Thymus Extracts; C031407:thymostimulin; D002444:Cefuroxime; D016305:Thymopentin